Cerebrolysin — neurotrophic extract from porcine brain tissue
In short
Mixture of neuropeptides and amino acids studied in models of neuroprotection and recovery following ischemic stress.
Overview
Cerebrolysin is a standardized neuropeptide preparation derived from purified porcine brain proteins, containing bioactive peptides and amino acids that exhibit neurotrophic and neuroprotective properties for stroke recovery, traumatic brain injury, and cognitive enhancement.
IV/IM administration provides optimal bioavailability and brain penetration of neuropeptides and neurotrophic factors
Molecular information
Research indications
Grouped by area. Each entry reflects a separate published hypothesis or clinical signal - not medical advice.
CARS-1 (Stroke 2016, n=520) - 30 ml IV daily for 10 days reduces 90-day disability (mRS ≤2) by ~7% vs placebo.
Наблюдавайте за алергични реакции при първото приложение. Препаратът обикновено се понася добре. Противопоказан при епилепсия и тежка бъбречна недостатъчност според официалната листовка. Клиничните доказателства показват смесени резултати. Някои големи проучвания са положителни, докато други са неутрални. Съществуват опасения относно достоверността на някои публикувани изследвания. Не е одобрен в САЩ, но се използва клинично в над 50 държави. Използвайте инфузионни комплекти за еднократна употреба, за да гарантирате стерилност. Сигнали за спиране: Тежки алергични реакции (анафилаксия, тежък обрив); Поява на гърчове; Значителни сърдечно-съдови събития по време на приложение; Тежка бъбречна дисфункция или влошаване на бъбречната функция.
4 peer-reviewed sources
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
CARS-1
Phase 3 | 30 ml IV daily | 10 days | -7% disability at 90 days
Stroke · 2016
View the studyInformation about Cerebrolysin is based on published scientific research and is intended for research purposes only. Not medical advice.
Products are for in vitro laboratory research only. Not approved for human consumption.
Other peptides
5-Amino-1MQ
5-Amino-1MQ is a small-molecule selective inhibitor of NNMT (nicotinamide N-methyltransferase), identified by Anthony Sauve (Cornell) in 2018. NNMT is a "metabolic sink" for methyl donors and NAD+ — suppressing it in adipocytes raises energy expenditure without reducing calorie intake.
ReadAdipotide
Adipotide is a target peptide developed by Wadih Arap and Renata Pasqualini (MD Anderson) for selective elimination of white adipose tissue. It binds prohibitin on adipocyte vasculature and induces apoptosis of the blood vessels supplying fat tissue — leading to nonsurgical fat reduction.
ReadAOD-9604
AOD-9604 is a modified C-terminal 16-amino-acid fragment of human growth hormone (177-191), supplemented with a tyrosine residue. Retains the lipolytic effect of the full molecule but without diabetogenic or GH-stimulating activity. Developed by Metabolic Pharmaceuticals (Australia) in the 1990s.
ReadARA-290
ARA-290 (Cibinetide) is an 11-amino-acid fragment of erythropoietin (EPO) developed by Anthony Cerami as a cytoprotective molecule without erythropoietic activity. It retains the tissue-protective effects of EPO without raising hematocrit — explaining its potential in diabetic neuropathy and cardiac applications.
ReadArgireline
Argireline is a synthetic acetylated hexapeptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) derived from SNAP-25 — the SNARE complex subunit mediating acetylcholine release at neuromuscular junctions. Topical application reduces muscle activity in expression areas — which is why Argireline is marketed as a "topical Botox alternative".
ReadBPC-157
BPC-157 is a 15-amino-acid fragment isolated from a protective protein in human gastric juice — hence the name Body Protection Compound. Over thirty years of research by Predrag Sikiric's group at the University of Zagreb (100+ peer-reviewed papers) establish its angiogenic action through the VEGFR2 receptor and its stimulation of fibroblasts. If you work with in vitro models of tendon, muscle or gut tissue, BPC-157 is among the most extensively documented regenerative peptides.
ReadNo comments yet. Be the first.
Comments are reviewed before publishing.
